Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.

Autor: Benjamin DJ; Hoag Family Cancer Institute, Newport Beach, CA, USA. David.Benjamin@hoag.org., Shrestha A; Cancer Registry of Greater California (CRGC), Public Health Institute, Sacramento, CA, USA., Fellman D; Cancer Registry of Greater California (CRGC), Public Health Institute, Sacramento, CA, USA., Cress RD; Cancer Registry of Greater California (CRGC), Public Health Institute, Sacramento, CA, USA.; Department of Public Health Sciences, University of California Davis, Davis, CA, USA., Lythgoe MP; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK., Rezazadeh Kalebasty A; Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA, USA.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Dec; Vol. 27 (4), pp. 792.

Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis.

Autor: Lythgoe MP; Department of Surgery & Cancer, Imperial College London, London, UK., Emhardt AJ; Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Naci H; Department of Health Policy, London School of Economics and Political Science, London, UK., Krell J; Department of Surgery & Cancer, Imperial College London, London, UK., Sullivan R; King's College London, Institute of Cancer Policy, London, UK., Aggarwal A; Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

Publikováno v: The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Sep 10; Vol. 46, pp. 101062. Date of Electronic Publication: 2024 Sep 10 (Print Publication: 2024).

The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020.

Autor: Gloy V; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland., Schmitt AM; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.; Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK., Düblin P; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland., Hirt J; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.; International Graduate Academy, Institute of Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.; Institute of Nursing Science, Department of Health, Eastern Switzerland University of Applied Sciences, St. Gallen, Switzerland., Axfors C; Department for Women's and Children's Health, Uppsala University, Uppsala, Sweden.; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA., Kuk H; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Pereira TV; Applied Health Research Centre (AHRC) Li Ka Shing Knowledge Institute of St. Michael's Hospital University of Toronto Canada.; Department of Health Sciences, University of Leicester, Leicester, UK., Locher C; Univ Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset), Rennes, France., Caquelin L; Univ Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset), Rennes, France., Walter-Claudi M; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland., Lythgoe MP; Department of Surgery & Cancer, Hammersmith Hospital, Imperial College London, London, UK., Herbrand A; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland., Kasenda B; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland., Hemkens LG; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA.; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.; Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany.

Publikováno v: International journal of cancer [Int J Cancer] 2023 Jun 15; Vol. 152 (12), pp. 2474-2484. Date of Electronic Publication: 2023 Feb 24.

Implications of FDA's marketing authorization of hereditary cancer testing.

Autor: Benjamin DJ; Hoag Family Cancer Institute, Newport Beach, CA, USA. Electronic address: David.Benjamin@hoag.org., Lythgoe MP; Department of Surgery and Cancer, Imperial College, London, Hammersmith Hospital, London, United Kingdom., Rezazadeh Kalebasty A; Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA, USA.

Publikováno v: Journal of cancer policy [J Cancer Policy] 2024 Jun; Vol. 40, pp. 100478. Date of Electronic Publication: 2024 Apr 12.

Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective

Autor: Blagden, SP, Yu, L-M, Ellis, S, Hughes, H, Shaaban, A, Fennelly-Barnwell, J, Lythgoe, MP, Cooper, AM, Maignen, FM, Buckland, SW, Kearns, PR, Brown, LC, Experimental Cancer Medicine Centres (ECMC) CID trials working group

Publikováno v: British Journal of Cancer. 128:474-477

In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b622962ef203109f2292377f740bcb0
https://doi.org/10.1038/s41416-022-02051-7